Decision that design-defect claims against generic manufacturers are pre-empted may have broad impact

On 24 June 2013, in Mutual Pharmaceutical Co. v. Bartlett, No. 12-142, 570 U.S. __ (2013), the United States Supreme Court held that generic manufacturers cannot be liable for state tort design-defect claims because federal law prevents them from changing a drug’s design.

Read more: Decision that design-defect claims against generic manufacturers are pre-empted may have broad impact


Download PDF Back To Listing
Loading data